#USA #Vero Beach #QOL Medical #CSID #breath test

QOL Medical Discontinues 13C-Sucrose Breath Test Program Sponsorship

In a significant shift for patients with Congenital Sucrase-Isomaltase Deficiency (CSID), QOL Medical, LLC announced on February 19, 2025, that it will end its sponsorship of the 13C-sucrose breath test program effective March 1, 2025. The breath test has been pivotal in diagnosing CSID, a condition affecting the ability to digest sucrose, commonly found in a variety of foods.

Impact on Patients

Previously, this test was provided free of charge to those exhibiting symptoms of CSID, thereby assisting with timely and accurate diagnosis. Following the discontinuation of QOL Medical’s sponsorship, patients will now face financial burdens, as they or their insurance companies will be responsible for the costs associated with the test if they wish to undergo it. Metabolic Solutions will continue to offer the test, providing a pathway for diagnosis, albeit at a cost.

Diagnosing CSID typically requires an in-depth review of one’s medical history, complemented by various tests, among which the breath test remains a significant diagnostic tool despite its impending changes in availability and financing.

What is Congenital Sucrase-Isomaltase Deficiency (CSID)?

CSID is a rare condition that is mainly characterized by difficulty in digesting sucrose. This can lead to a myriad of gastrointestinal symptoms that can be mistaken for other disorders, such as irritable bowel syndrome (IBS).

For older children and adults, symptoms may include chronic abdominal pain, excessive gas, bloating, and diarrhea. In infants, the clinical manifestations can be more severe, featuring explosive watery diarrhea, growth failure, diaper rashes, and overall irritability.

Due to its varied presentations, a solid understanding of the condition and access to diagnostic tools like the 13C-sucrose breath test are crucial for effective management and treatment.

QOL Medical's Commitment

Despite the changes regarding the breath test sponsorship, QOL Medical, LLC reassures its commitment to enhancing the lives of patients with rare diseases. The company, founded in 2003, is dedicated to identifying rare medical solutions and improving health outcomes by making essential medications accessible to populations affected by these conditions.

They encourage patients and healthcare professionals to reach out directly to Metabolic Solutions for any queries related to the testing process or reimbursement details. Metabolic Solutions can be contacted at 603-598-6960 or via email at [email protected].

As the healthcare landscape evolves, transitions such as the cessation of the sponsorship highlight the need for continued advocacy and support for patients navigating rare diseases. Maintaining awareness and facilitating dialogues about such changes will be integral to supporting affected individuals and their families during this transition phase in essential diagnostic services.